Comparison of Apixaban and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis after Total Knee Arthroplasty in Older Adults
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To compare the effect of apixaban and low molecular weight heparin (LMWH) in the prevention and treatment of deepvenous thrombosis (DVT) after total knee arthroplasty in older adult patients. Materials and Methods: A total of 220 patients (average age of 67.8±6.4 years) undergoing total knee arthroplasty were randomlyselected as research subjects and were divided into apixaban and LMWH groups (110 in each group). Results: The incidence of DVT was lower in the apixaban group than in the LMWH group (5.5% vs. 20.0%, p=0.001). Activatedpartial thromboplastin times (35.2±3.6 sec vs. 33.7±2.2 sec, p=0.010; 37.8±4.6 sec vs. 34.1±3.2 sec, p<0.001; 39.6±5.1 sec vs. 35.7±3.0sec, p=0.032) and prothrombin times (14.0±1.0 sec vs. 12.8±0.9 sec, p<0.001; 14.5±1.2 sec vs. 13.0±1.1 sec, p<0.001; 15.3±1.4 sec vs. 13.2±1.3 sec, p=0.009) in the apixaban group at 1 week after surgery, 3 weeks after surgery, and the end of treatment were higherthan those in the LMWH group. Platelet and fibrinogen levels in the apixaban group were lower than those of the LMWH group. Also, capillary plasma viscosity and erythrocyte aggregation in the apixaban group at 1 week after surgery, 3 weeks after surgery,and the end of treatment were lower than those in the LMWH group. Conclusion: Apixaban, which elicits fewer adverse reactions and is safer than LMWH, exhibited better effects in the preventionand treatment of DVT after total knee arthroplasty in older adults.
Abstract
Purpose: To compare the effect of apixaban and low molecular weight heparin (LMWH) in the prevention and treatment of deepvenous thrombosis (DVT) after total knee arthroplasty in older adult patients. Materials and Methods: A total of 220 patients (average age of 67.8±6.4 years) undergoing total knee arthroplasty were randomlyselected as research subjects and were divided into apixaban and LMWH groups (110 in each group). Results: The incidence of DVT was lower in the apixaban group than in the LMWH group (5.5% vs. 20.0%, p=0.001). Activatedpartial thromboplastin times (35.2±3.6 sec vs. 33.7±2.2 sec, p=0.010; 37.8±4.6 sec vs. 34.1±3.2 sec, p<0.001; 39.6±5.1 sec vs. 35.7±3.0sec, p=0.032) and prothrombin times (14.0±1.0 sec vs. 12.8±0.9 sec, p<0.001; 14.5±1.2 sec vs. 13.0±1.1 sec, p<0.001; 15.3±1.4 sec vs. 13.2±1.3 sec, p=0.009) in the apixaban group at 1 week after surgery, 3 weeks after surgery, and the end of treatment were higherthan those in the LMWH group. Platelet and fibrinogen levels in the apixaban group were lower than those of the LMWH group. Also, capillary plasma viscosity and erythrocyte aggregation in the apixaban group at 1 week after surgery, 3 weeks after surgery,and the end of treatment were lower than those in the LMWH group. Conclusion: Apixaban, which elicits fewer adverse reactions and is safer than LMWH, exhibited better effects in the preventionand treatment of DVT after total knee arthroplasty in older adults.
참고문헌 (22)
- Bonutti PM, "Novel venous thromboembolic disease (VTED) prophylaxis for total knee arthroplasty-aspirin and fish oil", Ann Transl Med, 5(Suppl 3), pp.S30~ (2017)
- Zhou LY, "Effects of inhalation anesthesia vs. total intravenous anesthesia (TIVA) vs. spinal-epidural anesthesia on deep vein thrombosis after total knee arthroplasty", Med Sci Monit, 24, pp.67~75 (2018)
- Falck-Ytter Y, "Prevention of VTE in orthopedic surgery patients. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2 Suppl), pp.e278S~e325S (2012)
- Wakabayashi H, "The risk factor of preoperative deep vein thrombosis in patients undergoing total knee arthroplasty", J Orthop Sci, 22, pp.698~702 (2017)
- Zou Y, "Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty", Blood Coagul Fibrinolysis, 25, pp.660~664 (2014)
- Warwick D, "Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events : findings from the Global Orthopaedic Registry", J Bone Joint Surg Br, 89, pp.799~807 (2007)
- Beyer-Westendorf J, "Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery : findings from the ORTHO-TEP registry", Thromb Haemost, 109, pp.154~163 (2013)
- Aryal MR, "Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery", J Community Hosp Intern Med Perspect, 5, pp.27889~ (2015)
- King DA, "Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty : a single-centre, single-surgeon, retrospective analysis", Intern Med J, 46, pp.1030~1037 (2016)
- Lassen MR, "Apixaban or enoxaparin for thromboprophylaxis after knee replacement", N Engl J Med, 361, pp.594~604 (2009)
- Cafri G, "Comparative effectiveness and safety of drug prophylaxis for prevention of venous thromboembolism after total knee arthroplasty", J Arthroplasty, 32, pp.3524~3528 (2017)
- Bala A, "Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?", Clin Orthop Relat Res, 475, pp.2205~2213 (2017)
- Kang J, "Analysis of risk factors for lower-limb deep venous thrombosis in old patients after knee arthroplasty", Chin Med J(Engl), 128, pp.1358~1362 (2015)
- Kuperman EF, "The effects of advanced age on primary total knee arthroplasty : a meta-analysis and systematic review", BMC Geriatr, 16, pp.41~ (2016)
- Pierce TP, "What’s new in venous thromboembolic prophylaxis following total knee and total hip arthroplasty? An update", Surg Technol Int, 26, pp.234~237 (2015)
- Lieberman JR, "Prevention of venous thromboembolic disease after total hip and knee arthroplasty", J Bone Joint Surg Am, 87, pp.2097~2112 (2005)
- Lazo-Langner A, "Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study", J Thromb Haemost, 12, pp.1626~1635 (2014)
- O’Donnell M, "Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty : a systematic review", Arch Intern Med, 163, pp.1362~1366 (2003)
- Li X, "Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-scorematched approach", PLoS One, 13, pp.e0191722~ (2018)
- Venker BT, "Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty : a meta-analysis", J Arthroplasty, 32, pp.645~652 (2017)
- Lanitis T, "Cost-effectiveness of apixaban versus low molecular weight heparin", vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences, 2017, pp.17, 74~
- Lassen MR, "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement", J Thromb Haemost, 5, pp.2368~2375 (2007)